Novavax , Inc. (Nasdaq: NASDAQ:NVAX), a developer of next-generation vaccines, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by the number of doses produced/sold, made an announcement, according to which the Drugs Controller General of India (DCGI) has granted emergency use authorization for Covovax, Novavax's protein-based COVID-19 vaccine, for adolescents of 12 years of age and older in India.
Covovax was initially granted an emergency use authorization for 18+ adults by DCGI in December and received Emergency Use Listing (EUL) from the World Health Organization (WHO), as well as EUA in Indonesia, the Philippines, and Bangladesh.
Shares of Novavax rose 0.8% after-hours on the news.
By Davit Kirakosyan